Skip to main content
. 2020 Jan 30;12(2):323. doi: 10.3390/cancers12020323

Figure 1.

Figure 1

Ixazomib inhibits osteoclastogenesis in human monocyte (MCs) cultures under osteoclast (OC) differentiation protocol. qRT-PCR analysis of mRNA levels of the osteoclastogenic markers RANK (A), CTSK (B), MMP9 (C) and CHI3L1 (D) in MC cultures exposed to the OC medium, MCs treated with Ixazomib, and MCs exposed to the OC medium and treated with Ixazomib. Representative pictures of control MCs, MCs exposed to OC medium, MCs treated with Ixazomib and MCs exposed to the OC medium treated with Ixazomib (1 nM). DAPI (blue); PHALLOIDIN (green); scale bar: 50 μm (E). CHIT1 enzymatic activity in MC cultures exposed to the OC medium, MCs treated with Ixazomib, and MCs exposed to the OC medium and treated with Ixazomib (F). OC medium—osteoclastogenic medium. * p-value < 0.05, ** p-value < 0.01 and *** p-value < 0.001 vs. control or between groups.